What will the average number of measles cases be during Trump's term?

**Stage 1 — Blind analysis (ignore market price):**

- The CDC reporting of 2,073 confirmed measles cases as of 11 June 2026 is the single most important hard datum. That count already exceeds many recent single-year totals and, if sustained or followed by further waves in later 2026 or 2027, would push a four-year average well above 1,000 cases/year. Measles is highly cluster-driven; when pockets of under-vaccination exist, outbreaks seed large, fast spikes that contribute disproportionately to multi-year averages.

- Key background conditions favoring elevated counts over multiple years include: reported declines in MMR coverage in school-aged cohorts (the cited ~92.5% or even lower figures in some posts), ongoing debate and criticism around federal public-health messaging (which can depress uptake and hamper outbreak control), and the documented instability of elimination status in the Americas in recent years. These create persistent susceptibility pockets and recurrent outbreak risk rather than one-off blips.

- Historical pattern: large U.S. measles outbreaks in the modern era (e.g., 2019) were driven by concentrated under-vaccinated communities and imported chains. If the 2026 surge reflects the same mechanics but on a larger or more geographically diffuse scale, expect follow-on outbreaks in 2027 and 2028 unless vaccination coverage improves rapidly and aggressively.

- Offsetting factors: measles outbreaks tend to burnout locally once susceptible pools are depleted or targeted vaccination campaigns are enacted. High case counts in 2026 could reduce susceptibles and lead to lower counts in subsequent years. State and local public-health responses, plus abatement via natural immunity in affected communities, can materially lower future incidence. Seasonality (school cycles) and targeted campaigns could also reduce average counts.

- Net blind assessment: given the very large 2026 count already observed and the structural risk factors (vaccine confidence issues and documented immunity gaps), I estimate a 72% chance the 4-year average exceeds 1,000 cases/year. This reflects a moderate-to-high likelihood that 2026 remains a large-contribution year and that some ongoing transmission or further outbreaks occur in 2027–2028, keeping the multi-year mean elevated.

**Stage 2 — Market calibration (look at current market prices):**

- The market currently prices Yes at 0.30 and No at 0.70. My independent 0.72 probability diverges substantially from the market. Possible reasons the market is pricing Yes so low: - Traders may anchor to pre-2026 low-case years (e.g., the many years with near-zero U.S. cases) and underweight the magnitude of the current 2026 surge. - Market participants may overestimate how quickly outbreaks burn out or how effective immediate public-health responses will be in lowering subsequent years. - Liquidity and attention: though volume is non-trivial (~148k contracts), the question framing may be confusing (no explicit threshold in the prompt) and some traders could be betting conservatively or misreading the question. - Political framing and polarized narratives might lead some traders to discount CDC counts as transitory or to expect rapid policy fixes; this creates a systematic underpricing of sustained high-case scenarios.

- Given these plausible market biases and the hard surveillance data showing >2,000 cases mid-2026, I believe the market is materially underpricing the probability of an elevated multi-year average. If you want to trade on this market, the edge appears to be on the 'Yes' side, unless the market's 'Yes' threshold is something materially higher than the 1,000/year assumption used here.

- Caveat: my stated probability assumes the implicit threshold for 'Yes' is average annual cases >1,000. If the actual market threshold differs, the calibration conclusion could change materially.